MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

GE HealthCare's AI initiatives, including AI-powered imaging solutions and strategic partnerships, are led by its chief AI ...

Clinical trials are a significant part of the drug development cycle. However, the process has remained unchanged in recent ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

Chronic fatigue and long Covid remain poorly understood, but Dr Perrin’s unusual techniques are having surprisingly positive ...

Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

She has devoted more than 40 years of service to research and clinical work with individuals suffering from Traumatic Brain Injury (TBI), publishing more than 500 journal articles and two books on TBI ...

A first healthy adults group has been dosed in an early clinical trial of an oral and myelin-protective treatment for all ...

They found many studies showing that the technology could be effective, but all provided the therapy in a clinical setting.